The Online Investor
Biotechnology M&A image Biotechnology M&A » By The Online Investor Staff, updated Mon., Jul. 4, 11:11 AM Recent mergers and acquisitions in the Biotechnology M&A category.

Slide #78. BioCryst Pharmaceuticals, Inc. Presidio Pharmaceuticals, Inc.

Acquirer: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
Acquiree: Presidio Pharmaceuticals, Inc.
Details: BioCryst Pharmaceuticals, Inc. and privately held Presidio Pharmaceuticals, Inc. today announced that the companies have signed a definitive merger agreement for Presidio to be acquired by BioCryst in an all-stock transaction. The transaction has been approved by the Boards of both companies. The transaction values Presidio at approximately $101 million, based on yesterday's closing BioCryst share price of $4.11 per share. The transaction is expected to close in the first quarter of 2013, and is subject to customary conditions, including approval by BioCryst shareholders.

BioCryst Pharmaceuticals is a commercial-stage biotechnology company that discovers oral, small-molecule medicines. Co. focuses on oral treatments for rare diseases. Co.'s drug/drug candidates include: ORLADEYO™ (berotralstat), an oral serine protease inhibitor targeting kallikrein that is being developed for the prevention of Hereditary Angioedema attacks; BCX9930, an oral factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors for the treatment of fibrodysplasia ossificans progressive; and RAPIVAB® (peramivir injection), an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza.

BCRX SEC Filing Email Alerts Service

Open the BCRX Page at The Online Investor »

Company Name: 
BioCryst Pharmaceuticals Inc
Number of ETFs Holding BCRX: 
Total Market Value Held by ETFs: 
Total Market Capitalization: 
% of Market Cap. Held by ETFs: 

Open the BCRX Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Email EnvelopeFree BCRX Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Buy (3.20 out of 4)
29th percentile
(ranked lower than approx. 71% of all stocks covered)

Analysts' Target Price:
BCRX Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Biotechnology M&A - Slide 78 of 83 Page |

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.